Literature DB >> 22340718

PAKs in human disease.

Perry M Chan1, Ed Manser.   

Abstract

The p21-activated kinases (PAKs) are one of the first direct kinase targets of Ras-related small GTPases to be discovered and have emerged as central players in growth factor signaling networks that regulate morphogenetic processes. In some situations, PAKs control cell proliferation, but their wider role involves establishing cell polarity and promoting cellular plasticity via changes in the actin cytoskeleton. PAKs have been shown to impact on three important areas of human health, namely, cancer, brain function, and virus infection. We review the mechanisms and targets of PAKs in these contexts and provide an overview of the ways in which inhibitors might act to arrest tumor growth, combat virus infection, and promote cell apoptosis. Although PAKs are most abundant in the brain, there are few details of how they might be operating in this context. The advent of new and more selective PAK inhibitors promises new avenues of treatment and allows us to probe in greater detail the importance of PAK biology. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22340718     DOI: 10.1016/B978-0-12-396456-4.00011-0

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  18 in total

Review 1.  Structure, biochemistry, and biology of PAK kinases.

Authors:  Rakesh Kumar; Rahul Sanawar; Xiaodong Li; Feng Li
Journal:  Gene       Date:  2016-12-19       Impact factor: 3.688

2.  Regulation of AMPA receptor subunit GluA1 surface expression by PAK3 phosphorylation.

Authors:  Natasha K Hussain; Gareth M Thomas; Junjie Luo; Richard L Huganir
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

Review 3.  Targeting Cdc42 in cancer.

Authors:  Luis E Arias-Romero; Jonathan Chernoff
Journal:  Expert Opin Ther Targets       Date:  2013-08-19       Impact factor: 6.902

4.  Arhgef7 promotes activation of the Hippo pathway core kinase Lats.

Authors:  Emad Heidary Arash; Ki Myung Song; Siyuan Song; Ahmed Shiban; Liliana Attisano
Journal:  EMBO J       Date:  2014-11-25       Impact factor: 11.598

5.  The three-dimensional landscape of cortical chromatin accessibility in Alzheimer's disease.

Authors:  Jaroslav Bendl; Mads E Hauberg; Kiran Girdhar; Eunju Im; James M Vicari; Samir Rahman; Michael B Fernando; Kayla G Townsley; Pengfei Dong; Ruth Misir; Steven P Kleopoulos; Sarah M Reach; Pasha Apontes; Biao Zeng; Wen Zhang; Georgios Voloudakis; Kristen J Brennand; Ralph A Nixon; Vahram Haroutunian; Gabriel E Hoffman; John F Fullard; Panos Roussos
Journal:  Nat Neurosci       Date:  2022-09-28       Impact factor: 28.771

6.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

7.  Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.

Authors:  Luis E Arias-Romero; Olga Villamar-Cruz; Min Huang; Klaus P Hoeflich; Jonathan Chernoff
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

8.  HIV-1 Nef and T-cell activation: a history of contradictions.

Authors:  Tristan J Markle; Mwimanzi Philip; Mark A Brockman
Journal:  Future Virol       Date:  2013-04-01       Impact factor: 1.831

9.  Crosstalk between casein kinase II and Ste20-related kinase Nak1.

Authors:  Lubos Cipak; Sneha Gupta; Iva Rajovic; Quan-Wen Jin; Dorothea Anrather; Gustav Ammerer; Dannel McCollum; Juraj Gregan
Journal:  Cell Cycle       Date:  2013-03-05       Impact factor: 4.534

10.  PAK in pathogen-host interactions.

Authors:  Jean-Philippe Semblat; Christian Doerig
Journal:  Cell Logist       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.